NCT04281953

Brief Summary

This project aims to explore, in depth, the burden of hearing loss and tinnitus on cancer survivors. Using semi-structured interviews, audiograms and a variety of validated questionnaires, the specific impact ototoxicity has on quality of life will be investigated. From this, we can identify the specific needs of patients experiencing hearing loss and tinnitus following chemotherapy and develop a tailored and personalised support system.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 20, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 24, 2020

Completed
4 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2020

Completed
Last Updated

March 25, 2020

Status Verified

March 1, 2020

Enrollment Period

6 months

First QC Date

February 20, 2020

Last Update Submit

March 24, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of hearing loss

    High frequency audiogram

    Between 0-5 years

Secondary Outcomes (3)

  • Quality of life Questionnaire SF-36 (short-form 36 item)

    Between 0-5 years

  • Hearing Questionnaire HHIA/HHIE (hearing handicap inventory for adults/elderly)

    Between 0-5 years

  • Tinnitus Questionnaire THI (tinnitus handicap inventory)

    Between 0-5 years

Study Arms (1)

People with ototoxicity

People living with and beyond who experience ototoxicity as a result of chemotherapy

Diagnostic Test: High frequency audiometryOther: Short-Form 36-Item Questionnaire (SF-36)Other: Hearing handicap inventory for adults/elderly (HHIA/HHIE)Other: Tinnitus handicap inventory (THI)

Interventions

Simple hearing test

People with ototoxicity

Questionnaire on quality of life (Short Form 36 Item- SF-36)

People with ototoxicity

Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)

People with ototoxicity

Questionnaire on Tinnitus (Tinnitus Handicap Inventory)

People with ototoxicity

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

People who have received platinum-based chemotherapy 0-5 years ago.

You may qualify if:

  • Has had platinum-based chemotherapy between 0-5 years ago
  • Has had at least 1 cycle- Was an adult (over 18) at the time of cancer diagnosis

You may not qualify if:

  • Pre-existing hearing issues
  • Radiotherapy to the head and neck area

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nottingham

Nottingham, Nottinghamshire, NG7 2RD, United Kingdom

Location

MeSH Terms

Conditions

NeoplasmsHearing Loss, SensorineuralTinnitus

Interventions

Aging

Condition Hierarchy (Ancestors)

Hearing LossHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Growth and DevelopmentPhysiological Phenomena

Study Officials

  • David Baguley, PhD

    University of Nottingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2020

First Posted

February 24, 2020

Study Start

September 5, 2019

Primary Completion

February 28, 2020

Study Completion

February 28, 2020

Last Updated

March 25, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Data will be anonymised and made confidential, statistical analysis will be performed before data is shared.

Locations